Financial results for March 31 , 2025

Going-concern doubtRelated-party transactionsNegative operating cash flowResults restatedNet loss reportedResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.0%Reaction day

₹13.07

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+4.6%-2.6% vs market

Pharmaceuticals peers, median of 148sector+2.8%-0.8% vs sector

On the reaction day the stock moved 2.6 pts less than Nifty Microcap 250 and 0.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.0+4.6-2.6+2.8-0.8

Next day

+4.0+6.3-2.3+4.2-0.2

+6.0+8.1-2.0+5.3+0.8

—+9.1—+5.5—

+8.1+10.0-1.9+6.2+1.9

+10.3+11.3-1.0+7.1+3.2

—+11.0—+6.4—

15d

—+13.3—+7.4—

—+15.3—+8.8—

+20.1+17.0+3.2+10.9+9.2

+25.5+11.4+14.0+5.9+19.6

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 148Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Adline Chem Lab Ltd submitted its audited standalone results for Q4 and FY25. The company reported a Q4 standalone profit of Rs 20.94 lakhs, swinging from a Q4 FY24 loss of Rs 8.27 lakhs. However, the full year remained in the red with a PAT loss of Rs 13.22 lakhs, though narrowed from Rs 27.18 lakhs in FY24. Total income for the year stood at Rs 24.89 lakhs, with the entire revenue appearing to come from a one-time modification of financial liabilities. The auditor's review flagged concerns about material modifications to a contract with related party Vivanza Lifescience Pvt Ltd, where prior shareholder approval for the transaction was not obtained. Operating cash flow stayed negative at Rs (22.61) lakhs. The board also approved a new Internal Auditor and Secretarial Auditor, while accepting the resignation of Company Secretary Mrs. Ritu Singh.

Likely market impact

Despite a Q4 profit, the company continues to post annual losses and has accumulated losses of Rs 733.95 lakhs against a share capital of Rs 585 lakhs, indicating serious going concern risks for shareholders. The auditor's specific emphasis on an unapproved related party transaction and persistent negative operating cash flow are red flags that could weigh on the stock price.